GLP-1S research

The GLP-1S evidence base cited here is 8 sources — 5 clinical, 2 regulatory. Its strongest evidence is human — 5 clinical studies, most recently 2023 ("Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SEL…"). Regulatory status: FDA-approved (Ozempic/Wegovy).

Cross-trial comparison only — different trials, populations, and endpoints. Only GLP-2T-vs-GLP-1S has been tested head-to-head (SURPASS-2), where GLP-2T won.

*GLP-3R's 28.7% is reported topline, pending peer-reviewed publication. See the GLP-2T and GLP-3R research pages for the full breakdowns. All three are built on the same His-Aib-Glu-Gly-Thr-Phe… N-terminal incretin backbone — what differs is the receptor targets (GLP-1 → +GIP → +glucagon), the fatty-acid chain and half-life (~7 / ~5 / ~6 days), and peak efficacy.

• GLP-1S is a GLP-1 receptor agonist from Novo Nordisk — the drug that turned GLP-1 therapy into a household name. FDA-approved as Ozempic (type 2 diabetes, 2017), Wegovy (weight management, 2021), and Rybelsus (oral diabetes).
• In the STEP 1 obesity trial it produced 14.9% mean weight loss at 68 weeks (vs 2.4% placebo), with about a third of participants losing ≥20%.
• The SELECT trial showed a 20% reduction in major cardiovascular events in overweight/obese adults without diabetes — proving the heart benefit is independent of blood-sugar effects.

It started as a diabetes drug (Ozempic, 2017), then earned a dedicated obesity approval (Wegovy, 2021) after trials showed double-digit weight loss. It's the single-receptor benchmark that the dual-agonist GLP-2T and the triple-agonist GLP-3R are measured against.

GI effects dominate, especially during escalation, and are mostly self-limiting.

• Metformin — well established in diabetes, complementary mechanism, additive weight benefit.
• Testosterone / anabolics — used to preserve lean mass during cutting, but evidence is weak: GLP-1S cuts skeletal muscle about as much as plain caloric restriction does.
• GH secretagogues (tesamorelin, ipamorelin) — experimental/off-label; both classes affect glucose, so caution.
• GLP-2T — switching between them is common, but do NOT run both at once (overlapping mechanism, no added benefit, much higher side-effect risk).

• Ozempic — approved 2017 for type 2 diabetes.
• Wegovy — approved 2021 for chronic weight management (and adolescents 12+ via STEP TEENS).
• Compounded GLP-1S sits in a gray area allowed during shortages; the FDA has warned about quality and incorrect salt forms (GLP-1S sodium vs base).

Research-grade GLP-1S sold 'not for human consumption' is unregulated — purchase is generally legal, but human use happens outside any quality oversight.

GLP-1S is not on the WADA Prohibited List and isn't banned in most sports. It does raise fairness questions in weight-class sports, and some bodies are monitoring GLP-1 use. A practical risk for tested athletes: compounded or research-grade products can contain undisclosed substances that trigger a positive test — verify status with your governing body.

On the Huberman Lab podcast, Dr. Abud Bakri credited pharma for the engineering behind GLP-1S: native GLP-1 (whose biology traces partly to Gila-monster-saliva research) is too short-acting, and the value was in extending its half-life into a usable drug. He noted that bodybuilders pioneered GLP-1 weight-loss use in the late 2010s before formal FDA weight-loss approval.

On staying on the drug, he leaned on set-point / settling-point theory — body weight is a daily brain calculation integrating many hormones, and a GLP-1 is a large 'don't eat' signal, so stopping often leads to regain. He worried less about lifelong use (cost and access permitting) than about the 'much shorter life of obesity,' while still asking his recurring 'free lunch?' question.

Expert clinical opinion; the framing is cautious optimism, not a recommendation, and GLP-1S should be used under medical supervision.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.